All In Biotech

Drug Trial Radar · NCT04703192

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Single-arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects With Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

155

Actual

Start

Jun 3, 2021

Primary completion

May 10, 2023

Study completion Jun 19, 2029

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Jan 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.

Conditions

  • Relapsed/Refractory Peripheral T-Cell Lymphoma
  • Adult T Cell Leukemia/Lymphoma

Interventions

  • Valemetostat TosylateDrug

    Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Objective Response As Assessed by Blinded Independent Central Review After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)Time frame: From baseline until disease progression or death (whichever occurs first), up to approximately 23 months
  2. Number of Participants With Treatment-emergent Adverse Events After Administration of Valemetostat Tosylate Monotherapy (Cohort 2)Time frame: From the time the informed consent form is signed up to 30 days after last dose, up to 23 months

Locations

60 sites in 12 countries. Site status is shown where the registry gives one.

  • City Of Hope National Medical Center

    Duarte, California

  • Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY

    Palo Alto, California

  • University of California San Francisco

    San Francisco, California

  • University Of Colorado Cancer Center

    Aurora, Colorado

  • Emory University Hospital - Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University - Feinberg School of Medicine

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center - John Theurer Cancer Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center at Memorial Hospital

    New York, New York

  • Weill Cornell Medicine

    New York, New York

  • Duke Cancer Center

    Durham, North Carolina

  • University of Pennsylvania Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania

  • Epworth Healthcare

    Richmond, Australia

  • Ottawa Hospital Research Institute

    Ottawa, Canada

  • University Health Network Princess Margaret Hospital

    Toronto, Canada

  • BC Cancer - Vancouver Centre

    Vancouver, British Columbia, Canada

  • CHU de Dijon

    Dijon, France

  • CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang

    Lille, France

  • Centre Lyon Berard - Medical Oncology

    Lyon, France

  • APHP - Hopital Saint Louis

    Paris, France

  • Hôpital Necker

    Paris, France

  • Centre Hospitalier Lyon Sud - Hématologie

    Pierre-Bénite, France

  • Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)

    Toulouse, France

  • Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV

    Halle, Germany

  • ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo

    Bergamo, Italy

  • A.O.di Bologna Policl.S.Orsola

    Bologna, Italy

  • PO San Gerardo, ASST Monza

    Monza, Italy

  • Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori

    Naples, Italy

  • Ospedale S.Maria della Misericordia, AO di Perugia, Università degli Studi di Perugia

    Perugia, Italy

  • Kyushu University Hospital

    Fukuoka, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • University Hospital - Kyoto Prefectural University of Medicine

    Kyoto, Japan

  • Nagasaki University Hospital

    Nagasaki, Japan

  • Okayama University Hospital

    Okayama, Japan

  • National Hospital Organization Nagoya Medical Center - Hematology

    Nagoya, Aichi-ken, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • Hokkaido University Hospital - Medical Oncology Center

    Sapporo, Hokkaido, Japan

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.